Alnylam Pharmaceuticals Stock News

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 11th Annual SVB Leerink Global Healthcare Conference, being held virtually, on Thursday, February 17, 2022 at 10:00 am ET. A live audio webcast of the call will be available on the Investors section of the Company’s website at www.alnylam.com/events. A replay will be available on the Alnylam website within

Biotechnology is so beaten down, relative valuation metrics suggest some stocks could more than double

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.

Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and

Alnylam reported positive 18-month results using its drug vutrisiran for the treatment of patients with ATTR with polyneuropathy. A PDUFA date is set for April 14, 2022, for the potential approval of

Alnylam Pharmaceuticals Inc (NASDAQ: ALNY ) has announced detailed data from HELIOS-A Phase 3 study of vutrisiran at 18 months in patients with transthyretin-mediated (ATTR) amyloidosis. Transthyretin amyloidosis is characterized by the buildup of abnormal deposits of a protein called amyloid (amyloidosis) in the body''s organs and tissues. The details follow topline data announced Full story available on Benzinga.com

Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) has announced detailed data from HELIOS-A Phase 3 study of vutrisiran at 18 months in patients with transthyretin-mediated (ATTR) amyloidosis. Transthyret

The shares of Alnylam Pharmaceuticals <> have bounced back from nearly an eight-month low on Wednesday after H.C

Former Alnylam Pharmaceuticals CEO John Maraganore, considered a pioneer of RNA therapeutics, has joined the board of Kymera Therapeutics.

WATERTOWN, Mass., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR ), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the appointment of John Maraganore, Ph.D. to its Board of Directors. Dr. Maraganore joins Kymera''s Board after having led Alnylam Pharmaceuticals as founding CEO and Director and transformed the field of RNA therapeutics for the last nearly 20 years. "John has been a true pioneer and an inspiration for the whole biotech industry. As founding CEO of Alnylam, he has built one of the most successful biotech companies, evolving RNA therapeutics into a commercial stage therapeutic reality for patients around the globe." said Nello Mainolfi, PhD, Co-Founder, President and Chief Executive Officer of Kymera Therapeutics. "Given our ambitions at Kymera to take a similar path and build a fully integrated global biopharma company based on targeted protein degradation, it is especially fitting and exceptionally exciting to welcome John to our Board of Directors and work with him directly to accomplish our goals and vision." "Targeted protein degradation is a very exciting field with real transformative potential.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company will present full 18-month results from the HEL

(RTTNews) - Alnylam Pharmaceuticals Inc. (ALNY) said that it expects its full year 2021 non-GAAP operating loss to be substantially improved relative to the prior year. As of on December 31, 2021, Alnylam had preliminary cash, cash equivalents, and marketable securities of about $2.4 billion, compared to $1.9 billion at December 31, 2020.

Novartis (NVS) partners with Alnylam (ALNY) to collaborate on the discovery and the development of siRNA-based targeted therapy to restore functional liver cells.